(33) Priority Country:

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| ſ | (51) International Patent Classification 4: | | (11) International Publication Number: | WO 88/ 01293 |
|---|---|----|--|-----------------------|
| | C12N 9/54, C11D 3/386 | A1 | (43) International Publication Date: 25 Feb. | ruary 1988 (25.02.88) |

DK

(21) International Application Number: PCT/DK87/00101 (74) Agent: NO Allé, DK-

(22) International Filing Date: 14 August 1987 (14.08.87)

(31) Priority Application Number: 3865/86

(32) Priority Date: 14 August 1986 (14.08.86)

(71) Applicant (for all designated States except US); NOVO

(71) Applicant (for all designated States except US): NOVO INDUSTRI A/S [DK/DK]; Novo Allé, DK-2880 Bagsvaerd (DK).


(72) Inventors; and
(75) Inventors/Applicants (for US only): OUTTRUP, Helle
[DK/DK]; Syvendehusvej 46, DK-2750 Ballerup
(DK). DAMBMANN, Claus [DK/DK]; Høje Gladsaxe 61, 7.th., DK-2860 Søborg (DK). BRANNER,
Sven [DK/DK]; Ved Smedebakken 7A, DK-2800
Lyngby (DK).

(74) Agent: NOVO INDUSTRI A/S; Patent Dept., Novo Allé, DK-2880 Bagsvaerd (DK).

(81) Designated States: AT (European patent), BE (European patent), CH (European patent), DE (European patent), DK, FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent), US.

Published
With international search report.

(54) Title: ALKALINE PROTEASE DERIVED FROM BACILLES PRODUCTION AND USE THEREOF



(57) Abstract

Protease derived from a novel alkalophilic Bacillus species exhibits a remarkably enhanced stability towards bleaching agents of the peroxy type and is useful in detergents.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| AT | Austria | FR | France | ML | Mali |
|----|------------------------------|----|------------------------------|------|--------------------------|
| ΑÜ | Australia | GA | Gabon | . MR | Mauritania |
| BB | Barbados | GB | United Kingdom | MW | Malawi |
| BE | Belgium | HU | Hungary | NL | Netherlands |
| BG | Bulgaria | TT | Italy | NO | Norway |
| BJ | Benin | JР | Japan | RO | Romania |
| BR | Brazil | KP | Democratic People's Republic | SD | Sudan |
| CF | Central African Republic | | of Korea | SE | Sweden |
| CG | Congo | KR | Republic of Korea | SN | Senegal |
| CH | Switzerland | LI | Liechtenstein | SŲ | Soviet Union |
| CM | Cameroon | LK | Sri Lanka | TD | Chad |
| DE | Germany, Federal Republic of | LU | Luxembourg | TG | Togo |
| DK | Denmark | MC | Мопасо | US | United States of America |
| FT | Finland | MG | Madagascar | | • |

WO 88/01293 PCT/DK87/00101

1

Alkaline protease derived from Bacillus production and use thereof

The present invention is directed to a novel alkaline protease preparation having enhanced oxidation stability, to a method for the preparation thereof, and to its use as an additive for cleaning agents. Typical cleaning agents are detergent compositions for laundering.

BACKGROUND OF THE INVENTION

Proteolytic enzymes produced by cultivation of members of the genus <u>Bacillus</u> in suitable nutrient media are 10 widely used in detergent compositions. Examples of such commercial protease products are ALCALASE, ESPERASE and SAVINASE (these are registered trade marks), all supplied by NOVO Industri A/S, Denmark. These exhibit adequate storage stability in the presence of the usual components of detergent compositions, such as sequestering agents, surfactants and even bleaching agents of the peroxy type, provided that they are suitably protected from their physical environment in the detergent composition, for example by their incorporation into suitably coated particles.

However, in the laundering process where the solubilized enzyme is exposed to the same agents in solution, stability may become critical in the sense that the enzyme is prone to destruction prior to the completion of its intended stain-removing action, particularly at elevated temperatures in the presence of bleaching agents of the peroxy type, such as percarbonate, perborate, and persulfate salts. Since all Bacillus-derived proteases known in the art exhibit an appreciable instability at laundering temperatures exceeding 50°C in the presence of a peroxy compound it is often recommended to prolong the washing programme by including a holding time at lower temperature when detergent protease compositions are used.

Attempts to enhance the stability of <u>Bacillus</u> derived serine proteases towards oxidizing agents by applying the technique of site specific mutation to the corresponding genes is known in the art, e.g. from European Patent

- 5 Publication No. 0 130 756 which discloses stabilized subtilisins by substituting the methionine residue next to the active-site-serine residue with amino acid residues which are less prone to oxidation. However, the obstacles associated with the adaption of recombinant DNA strategies to
- large scale manufacturing processes are well-known, the most frequent ones being instability of the engineered microorganism through loss of genetic material and lower yields compared with those obtained from the wild strain or its conventional mutants.
- As far as the inventors hereof are aware the prior art is silent about non-engineered <u>Bacillus</u> derived serine proteases exhibiting an enhanced stability towards oxidation as compared with commercial <u>Bacillus</u> proteases.
- The object of the present invention is to overcome 20 the above-mentioned instability problems encountered with the Bacillus-derived alkaline protease preparations known heretofore. According to the invention this object has been met in that it has surprisingly been found that a number of Bacillus strains belonging to what is presently defined as
- 25 the same novel species produce alkaline protease which exhibits a remarkably enhanced stability towards bleaching agents of the peroxy type conventionally used for laundering.

Normally, the alkaline protease produced by the novel <u>Bacillus</u> species of this invention will contain three 30 main constituent, mutually distinguishable alkaline proteases (herein designated A, B and C) often in proportions, measured in protease activity units, of roughly one third of each. However, variant strains may lack the capability of producing at least one of these constituent proteases. Fortuitously,

35 all three constituent proteases show similar detergency and stability characteristics.

SUMMARY OF THE INVENTION

Thus, according to its first aspect the present invention provides a protease preparation comprising alkaline protease derived from a novel alkalophilic Bacillus species defined by the strains NCIB 12288 and NCIB 12289 which alkaline protease retains a residual activity measured in Casein Protease Units (CPU, vide infra) after 30 minutes at pH 9.5 in a solution of 1.75 g/l of sodium tripolyphospate (STPP), 1.0 g/l of sodium perborate and 0.1 g/l of tetraacetylethylenediamine (TAED) of at least 80% and 60% at temperatures of 40°C and 50°C, respectively, of the residual activity at 25°C in the absence of sodium perborate and TAED.

Another aspect of the present invention provides a protease preparation comprising at least 10% by activity in 15 CPU of a constituent protease A which is immunochemically identical to the protease identified by the position of peak A in fig. 1 of the accompanying drawings and has the following additional characteristics: a molecular weight of about 41.5 kD, an isoelectric point of about 9.3, a specific 20 activity of at least 150 Anson Units and 250 Hemoglobin Protease Units (AU and HPU, respectively, vide infra) per gm of protein, and a residual activity measured in CPU after 30 minutes at pH 9.5 in a solution of sodium tripolyphosphate (STPP, 1.75 g/l), sodium perborate (1.0 g/l), and

25 tetraacetylethylenediamine (TAED, 0.1 g/l) of at least 80% and 60% of temperatures of 40°C and 50°C, respectively, of the residual activity at 25°C in the absence of sodium perborate and TAED.

In a preferred embodiment the protease preparation 30 is essentially devoid of proteases B and C, identified by peak B of fig. 1 and by peak C of fig. 1 and 2, respectively.

In yet another preferred embodiment of the invention the balance of the protease activity is provided jointly by said proteases B and C or singly by either of them. Immunochemically, proteases B and C are identical to

each other and different from protease A. Protease B and C have molecular weights of about 28.5 and 31 kD and isoelectric points of about 8.8 and 5.2, respectively.

The present invention further provides a protease 5 preparation comprising essentially said protease B.

In addition, the present invention is directed to a protease preparation comprising essentially said protease C.

According to a further aspect of this invention there is provided a method for producing a protease

- 10 preparation, which process is characterized by cultivating a strain of the novel <u>Bacillus</u> species defined by the strains NCIB 12288 and NCIB 12289 under aerobic conditions in a nutrient medium containing assimilable sources of carbon, nitrogen, and phosphorus, preferably followed by recovery of the protease preparation from the fermentation broth.
- In a preferred embodiment of producing the protease preparation the fermentation is conducted with a strain of the <u>Bacillus</u> species defined above, which strain is mutated so as to essentially block its capability of synthesizing one 20 or two of the constituent proteases whilst maintaining its capability of producing the remaining constituent protease or proteases.

In another preferred mode of producing the protease preparation the fermentation is conducted with a <u>Bacillus</u>
25 strain selected from the group consisting of NCIB 12288, NCIB 12289, NCIB 12512 and NCIB 12513.

According to yet another aspect there is provided a cleaning agent containing an effective amount, preferably at least 0.1 AU, more preferred from 0.5 to 10 AU, of the 30 protease preparation of this invention per 100 g of cleaning agent. The cleaning agent may be a powder or a liquid wherein the protease preparation is protected, for example by incorporation into granules or as a suspension in a hydrophobic medium.

BKIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 shows the elution chromatogram of the protease preparation derived from NCIB 12289 on a CM Sepharose® CL 6B column, subsequent to gel filtration on 5 Sephadex® G 25.

Fig. 2 shows affinity chromatography of protease C on a bacitracin column.

Figs. 3 and 4 are exemplary of the pH-activity and temperature-activity curves, respectively, of the protease 10 preparation of this invention, all protease components exhibiting similar temperature- and pH-activity characteristics.

Figs. 5 and 6 illustrate the results of comparative washing experiments conducted with the protease preparation 15 of this invention and ALCALASE using two different detergents. Experimental conditions are given in Example 5 hereinafter.

Fig. 7 illustrates the results of washing experiments conducted with each of the constituent proteases.

20 DETAILED DESCRIPTION OF THE INVENTION

The microorganism, taxonomy, morphology, biochemical reactions

The microorganism:

The microorganisms productive of the alkaline

25 protease of the present invention were isolated essentially
by the method for the selection of alkalophilic <u>Bacilli</u>
described in British Patent No. 1,243,784. They will not grow
on ordinary media for <u>Bacillus</u> strains unless these are
supplemented by either 0.1 M carbonate buffer, pH 9.0 - 9.7

30 or a 7 - 10% (w/v) solution of NaCl, the 0.1 M carbonate
buffer, pH 9.0 being the preferred supplement. Two cultures

have been deposited with The National Collection of Industrial Bacteria (NCIB), Torry Research Station, Aberdeen, United Kingdom for the purposes of patent procedure on the date indicated below. NCIB, being an international depository authorized under the Budapest Treaty of 1977, affords permanence of the deposit and accessability thereto by the public in accordance with Rules 9 and 11, respectively, of the above treaty.

| Date of Deposit | Depositor's Reference | NCIB Designation |
|-----------------|-----------------------|------------------|
| 10 8 July 1986 | C608 | 12288 |
| 8 July 1986 | C609 | 12289 |
| 5 August 1987 | C610 | 12512 |
| 5 August 1987 | C611 | 12513 |

Taxonomy:

Medium TY was used for taxonomic investigations which were conducted according to the methods of Ruth Gordon et al. (The Genus Bacillus, Agriculture Handbook no. 427, U.S.D.A. 1973)

Composition of medium TY:

| 20 | Trypticase | 20 | g |
|----|--------------------------------------|------|-----|
| | Yeast extract | 5 | g |
| | FeCl ₃ .6H ₂ O | 7 | mg |
| | MnCl ₂ .4H ₂ O | 1 | mg |
| | $MgSO_4.7H_2O$ | 15 | g |
| 25 | distilled H O to | 1000 | m 7 |

pH adjusted to 7.3 with KOH before autoclaving for 15 min at $121^{\circ}\mathrm{C}$.

Liquid media for the determination of the production of acid from carbohydrates were supplemented with 10% NaCl before autoclaving.

Solid media were supplemented with 2% agar before 5 autoclaving and sterile carbonate buffer pH 9.0 was aseptically added to a final concentration of 0.1 M just before pouring the slants.

The microorganisms of this invention are aerobic, spore forming bacteria belonging to the genus <u>Bacillus</u>.

Morphology: Vegetative rods with a diameter of 0.6 - 0.8 micron, length 1.2 - 3 micron.

Spores: Central to subterminal, oval, not swelling the sporangia.

| | Biochemical reactions: | NCIB 12288 | NCIB 12289 |
|----|-----------------------------------|------------|------------|
| 15 | Production of catalase | . + | +. |
| | Production of acetoin (VP-test) · | - | |
| | Production of indole | _ | - |
| | Anaerobic growth | - | _ |
| | Growth at 50°C | - | _ |
| 20 | Growth in 7% NaCl | + | + |
| | Growth at pH 5.7 | _ | - |
| | Hydrolysis of starch | + | + |
| | Hydrolysis of hippurate | - | - |
| | Hydrolysis of casein | + | + |
| 25 | Hydrolysis of tyrosine | + | + |
| | Deamination of phenylalanine | - | - |
| | Reduction of nitrate to nitrite | _ | _ |
| | Acid from glucose | + | + |
| | Acid from sucrose | + | + |
| 30 | Acid from xylose | · + | |
| | Acid from mannitol | (+) | (+) |

None of the strains NCIB 12288 and NCIB 12289 produced acid from arabinose, mannose, melibiose, raffinose, or sorbitol.

Optimal growth conditions are 30 - 37°C, pH 9.0.

The above taxonomic results show that the two strains do not belong to any previously described species, but should be considered to define a novel Bacillus species.

Taxonómic data for strains NCIB 12512 and NCIB 12513 are very similar to the above, indicating that all four strains belong to the same species.

Assay for proteolytic activity

OPA-Casein method

Proteolytic activity is determined with casein as the substrate. One Casein Protease Unit (CPU) is defined as the amount of enzyme liberating 1 millimole of primary amino groups (determined by comparison with a serine standard) per minute under standard conditions, i.e. incubation for 30.

15 minutes at 25°C and pH 9.5.

A 2% (w/v) solution of casein (Hammarsten, supplied by Merck A.G., West Germany) is prepared with the Universal Buffer described by Britton and Robinson (Journ.Chem.Soc. 1931, p. 1451), adjusted to pH 9.5.

- Two ml of substrate solution is preincubated in a water bath for 10 minutes at 25°C. 1 ml of enzyme solution containing b g/ml of enzyme preparation, corresponding to about 0.2 0.3 CPU/ml of Britton-Robinson buffer (pH 9.5), is added. After 30 minutes of incubation at 25°C the reaction 25 is terminated by the addition of a stopping agent (5 ml of a solution containing trichloroacetic acid (17.9 g), sodium
- solution containing trichloroacetic acid (17.9 g), sodium acetate (29.9 g), and acetic acid (19.8 g), filled up to 500 ml with deionized water). A blank is prepared in the same manner as the test solution, except that the stopping agent 30 is added prior to the enzyme solution.

The reaction mixtures are kept for 20 minutes in the water bath, whereupon they are filtered through Whatman $^{\otimes}$ 42 paper filters.

Primary amino groups are determined by their colour development with o-phthaldialdehyde (OPA).

Disodium tetraborate decahydrate (7.62 g) and sodium dodecylsulfate (2.0 g) is dissolved in 150 ml of 5 water. OPA (160 mg) dissolved in 4 ml of methanol is then added together with 400 μ l of beta-mercaptoethanol, whereafter the solution is made up to 200 ml with water.

To the OPA reagent (3 ml) is added 400 μl of the above-mentioned filtrates with mixing. The optical density 10 (OD) at 340 nm is measured after about 5 minutes.

The OPA test is also performed with a serine standard containing 10 mg of serine in 100 ml of Britton-Robinson buffer (pH 9.5). The buffer is used as a blank.

The protease activity is calculated from the 15 optical density measurements by means of the following formula:

CPU/ml of enzyme solution =
$$\frac{(OD_t - QD_b) \times C_{ser} \times Q}{(OD_{ser} - OD_B) \times MW_{ser} \times t_i}$$

20 CPU/g of enzyme preparation = CPU/ml: b

wherein OD_t, OD_{ser} and OD_B is the optical density of the test solution, blank, serine standard, and buffer, respectively, C_{ser} the concentration of serine in mg/ml in the standard, MW_{ser} the molecular weight of serine. Q is the dilution factor (in this instance equal to 8) for the enzyme solution, and t_i is the incubation time in minutes.

OPA-hemoglobin method

Proteolytic activity is determined with ureadenatured hemoglobin as the substrate. One Hemoglobin 30 Protease Unit (HPU) is defined as the amount of enzyme liberating 1 millimole of primary amino groups (determined by comparison with a serine standard) per minute under standard conditions, i.e. incubation for 30 minutes at 25°C and pH 9.5.

A 2% (w/v) solution of urea-denatured hemoglobin is 5 perpared with 0.2 M borate buffer, adjusted to pH 9.5.

Two ml of substrate solution is preincubated in a water bath for 10 minutes at 25°C. 1 ml of enzyme solution containing b g/ml of enzyme preparation, corresponding to about 0.2-0.3 HPU/ml of borate buffer, is added.

10 Incubation, termination of the reaction and determination of primary amino grups by means of the OPA reagent are the same as those described above for the OPA-casein method.

The OPA test is also performed with a serine standard containing 10 mg of serine in 100 ml of the borate 15 buffer, the buffer itself serving as a blank.

The protease activity in HPU is calculated from a formula identical to that used in the OPA-casein method.

Modified Anson-hemoglobin method

In the Anson-hemoglobin method for the

20 determination of proteolytic acitivty, denatured hemoglobin
is digested under standard conditions. The undigested
hemoglobin is precipitated with trichloroacetic acid (TCA)
and the amount of TCA soluble product is determined with
Folin-Ciocalteu phenol reagent.

- One Anson Unit (AU) is the amount of enzyme which under standard reaction conditions digests hemoglobin at such an initial rate that there is liberated per minute an amount of TCA soluble product which gives the same colour with phenol reagent as one milliequivalent of tyrosine.
- The standard reaction conditions are the following: Temperature 25°C; reaction time 10 min.; pH 7.5.

For further reference, see M.L. Anson, Journal of General Physiology vol. 22 (1939), pp. 79-89; O. Folin and V. Ciocalteu, The Journal of Biological Chemistry vol. 73 35 (1972), pp. 627-636.

Different values for proteolytic activity will invariably be obtained depending on the choice of analytical method. While the OPA-casein assay is convenient for monitoring proteolytic activity for laboratory and production 5 purposes, it may be said that proteolytic activity towards a porphyrin containing substrate, such as hemoglobin, is more relevant for assessing the utility of a detergent protease because of the generally experienced difficulties with removal of stains from blood and chlorophyll. A high specific activity of a detergent protease towards porphyrin containing substrates is desirable.

The protease preparation

The <u>Bacillus</u> strains productive of the protease of this invention are cultivated under aerobic conditions in a 15 nutrient medium containing assimilable carbon and nitrogen . together with other essential nutrients, the medium being composed in accordance with the principles of the known art.

Suitable carbon sources are carbohydrates, such as sucrose, glucose and starch, or carbohydrate containing

20 materials such as cereal grains, malt, rice and sorghum.

Polysaccharides are usually at least partially converted into fermentable sugars by suitable hydrolyzing enzymes prior to the fermentation process. The carbohydrate concentration incorporated in the medium may vary widely, e.g. up to 25%

25 and down to 1 - 5%, but usually 5 - 15% will be suitable, the percentages being calculated as equivalents of glucose.

The nitrogen source in the nutrient medium may be of inorganic and/or organic nature. Suitable inorganic nitrogen sources are nitrates and ammonium salts. Among the organic nitrogen sources quite a number are regularly used in fermentation processes involving the cultivation of bacteria. Illustrative examples are soybean meal, cotton seed meal, peanut meal, casein, corn steep liquor, yeast extract, urea, and albumin. In addition, the nutrient medium should also contain the usual trace substances.

The optimum temperature for propagation of the Bacillus strains and for their production of protease is routinely ascertained by the skilled artisan. The cultivation may be conducted in the temperature range of from 25°C to 5 35°C, preferably at alkaline pH values. The latter may be obtained by addition of suitable buffers, such as sodium carbonate or mixtures of sodium carbonate and sodium bicarbonate after sterilization of the growth medium. For cultivation in tank fermentors it is necessary to use 10 artificial aeration. The rate of aeration is similar to that used in conventional tank fermentation.

After fermentation, liquid enzyme concentrates may be produced by removal of coarse material from the broth and, if desired, concentration by evaporation at low temperature 15 or by reverse osmosis. Finally, perservatives may be added to the concentrate.

Solid enzyme preparations may be prepared from the purified and/or concentrated broth by precipitation with salts, such as Na₂SO₄ or with water miscible solvents, such 20 as ethanol or acetone; removal of the water in the broth by suitable drying methods such as spray-drying may also be employed.

The proteolytic activity of the protease preparation so obtained is usually in the range of from 0.1 25 to 10 CPU/g.

The pH-activity and temperature-activity curves of protease according to this invention are shown in fig. 1 and 2. The sample used was that prepared in example 1 below, and activity was determined by the CPU method described above, except that pH or temperature was changed. The curves show that optimum pH with casein as substrate is about 6 to 11, and that optimum temperature for 30 minutes reaction is about 50-60°C.

Purification of Constituent Proteases

The first, second and third protease (hereinafter referred to as protease A, Protease B and protease C, respectively) may be separated and purified by separation 5 techniques generally known by the skilled artisan.

An initial purification of the crude protease may be effected by dissolution, e.g. in a suitable buffer, followed by protein precipitation, e.g. with a salt, such as $(NH_4)_2SO_4$, or a water-miscible organic solvent, for example acetone.

Further purification of the recovered precipitate is usually attained by chromatographic methods, for example including gel filtration in a buffer system as the initial step. Protease containing fractions of the eluate may be located by monitoring U.V. absorbancy and/or by determining the protease activity.

Following gel filtration further purification is usually achieved by ion exchange chromatography, for example on a SEPHADEX® anion or cation exchanger, whereby at least 20 partial resolution of the constituent proteases may be effected, by using suitable buffer-salt-gradient systems. Rechromatography of peak material therefrom by means of the same or a different ion exchanger usually affords the protease species in a sufficiently pure state. If required, 25 further purification of the individual proteases may be achieved by subjecting them to affinity chromatography, for example on a bacitracin column.

Purification of the constituent proteases is conveniently monitored by gel electrophoresis, for example in 30 a polyacrylamide gel (PAGE) with or without sodium dodecylbenzenesulphonate (SDS). Autodigestion of the proteases may be prevented by active site blocking prior to electrophoresis, for example with phenylmethylsulphonyl fluoride (PMSF).

SDS-PAGE and isoelectric focusing (IEF) in the presence of marker proteins are convenient means for molecular weight (MW) and isoelectric point (pI)

determinations, respectively. According to these methods, proteases A, B and C have molecular weights of about 41.5, 28.5 and 31.0 kD, and isoelectric points of about 9.3, 9.2 and 5.2, respectively. Protease A is further characterized by specific activities per gram of protein of about 180 AU/g and 270 HPU/g.

Immunochemical Characterization

Monospecific antisera against each of the purified proteases may be raised for example by immunizing rabbits 10 according to the regimen described by N. Axelsen et al. in: A manual of Quantitative Immunoelectrophoresis, Blackwell Scientific Publications, 1973, chapter 23. Purified immunoglobulins may be obtained from the antisera, for example by salt precipitation ((NH₄)₂SO₄), followed by 15 dialysis and ion exchange chromatography, e.g. on DEAE-Sephadex.

Immunochemical characterization of proteins is usually conducted either by Ouchterlony double-diffusion analysis (O. Ouchterlony in: Handbook of Experimental Immunology (D.M. Weir, Ed.), Blackwell Scientific Publications, 1967, pp. 655-706) or by crossed

Publications, 1967, pp. 655-706) or by crossed immunoelectrophoresis (N. Axelsen et al., supra, chapters 3 and 4).

Proteases B and C of the invention show

25 immunochemical identity to each other, and both show nonidentity to protease A. Proteases A, B and C of the invention
all show immunochemical non-identity to the following known
alkaline Bacillus proteases:

- Alcalase (product of Novo Industri A/S, Denmark), derived from <u>Bacillus licheniformis</u>, with Subtilisin Carlsberg as the active component.

- Savinase and Esperase (products of Novo Industri A/S), prepared from alkalophilic <u>Bacillus</u> <u>sp.</u> according to US 3,723,250.
- API-21 (U.S. patent 4,480,037).
- 5 The protease of Danish patent application No. DK 87/0544.

Cleaning agent

Cleaning agent according to the invention is typically a laundry detergent in liquid or powder form. In the case of a liquid detergent, the stability of the protease 10 during storage may be unsatisfactory, and it is therefore preferred to include enzyme stabilizers in the formulation. Thus, the liquid formulation may include polyols such as 1,2-propanediol (propylene glycol), typically 1 - 20%. Optionally, the formulation may include boric acid (or 15 alternatively, boric oxide, borax or a borak), typically up to 10%. Also optionally, formate or a salt of other lower fatty acid may be included, e.g. in an amount up to 10%. The calcium content in the liquid detergent may be from 0.001 to 0.1% (all %'es by weight).

20 Example 1

Protease preparation derived from strain NCIB 12289

Cells of <u>Bacillus</u> strain NCIB 12289 were harvested after 2 days' incubation at 30°C from slants of TY-agar supplemented aseptically with 0.1 M carbonate buffer pH 9.0 and 1% skim milk. The cells were transferred to 500 ml baffled shake flasks containing 100 ml BP-X medium + 0.1 M carbonate buffer pH 9.0.

| м | _ | a | i | um | P | ם | - v | ٠. |
|-----|---|---|---|----|-------|---|------------|-----|
| ניו | ᆮ | u | | ши | - 13. | _ | -, | . : |

| | potato starch | 100 | g |
|---|--|-----|---|
| | barley flour | 50 | g |
| | soy bean flour | 20 | g |
| 5 | Na-caseinate | 10 | g |
| | Na ₂ HPO ₄ .12H ₂ O | 9 | g |
| | TERMAMYL® 60L (NOVO) | 0.1 | g |
| | PLURONIC TM | 0.1 | g |
| | tap water to 1000 ml | | |

- The mixture was slowly heated from 60°C to 85°C during 30 minutes with agitation in order to liquefy the starch. The mixture was then heated quickly and kept above 95°C for 10 minutes before it was cooled, distributed into the shake flasks and autoclaved for 40 minutes at 121°C.
- The inoculated shake flasks were incubated for 4 days at 25°C on a rotary shaker at 240 rpm. The fermentation broth (2.5 l, 54 CPU/l, as assayed by the OPA-casein method) was centrifuged for 30 minutes at 4000 rpm. The centrifuged liquid (2.0 l) was concentrated to 1.0 l by ultrafiltration
- on a Mini-lab module from DDS, RO-Division, Denmark. After the concentration it was washed with 5.0 l of 0.01 molar sodium borate, pH 9.0, and finally concentrated further to 400 ml. It was then lyophilized, giving 25.5 g of crude preparation with an activity of 3.0 CPU/g. Yield: 57%.

Example 2

Separation of constituent proteases A, B and C

Fermentation with NCIB 12289 was performed essentially as in Example 1. The culture broth (75 AU/kg) was 5 purified through the following steps:

- flocculation
- centrifugation
- evaporation
- blank filtration
- salt precipitation with Na₂SO₄
 - redissolution
 - blank filtration
 - sterile filtration
 - concentration by ultrafiltration and washing
- lyophilization

. The lyophilized crude preparation (activity 15.3 $\dot{\text{CPU/g}}$ or 24.5 $\dot{\text{AU/g}}$) was purified and separated into constituent proteases by the following sequence of steps.

1. Redissolution

 $2.5\ \mathrm{g}$ of protease was dissolved in 50 ml of the following buffer:

dimethylglutaric acid 0.01 ${\tt M}$

boric acid 0.1 M

calcium chloride 0.002 M

sodium hydroxide to pH 7.0

2. Centrifugation

The redissolved protease was centrifuged at 18000 rpm at 25 - 30°C for 20 minutes.

3. Filtration

The supernatant was filtered on Whatman glassfilter type GF/F, 42 ml of clarified protease solution was collected.

5 4. Gelfiltration of Sephadex G 25 medium

40 ml of clarified protease solution was applicated to a G 25 column (5 cm0 x 22.6 cm) equilibrated with the buffer used in step 1. 10 ml fractions were collected, with a flow rate of 3.3 ml/min., and tested for activity. Fractions 10 19 - 25, comprising 54% of the applicated activity, were pooled, diluted to 100 ml and filtered on Millipore 0.45 μ filter type HA.

5. Ion exchange chromatography on CM Sepharose CL 6B

- The filtered eluate was applicated on a CM

 15 Sepharose CL 6B column (5 cm0 x 7.8 cm) equilibrated with the buffer used in step 1. Protease C and colored substances were washed out of the column with the same buffer. The other components were eluted with a 0 0.05 M NaCl gradient in 2 l of the same buffer. 10 ml fractions were collected, with a
- 20 flow rate of 3.3 ml/min., and monitored by UV-absorbance. The gradient was started after fraction 37. The UV-absorbing fractions 5 40 and 71 150 were tested for protease activity. The protease activity was found in 3 distinctive peaks, as seen in fig. 1.
- 25 Fractions 9 25, comprising 23.1% of the applicated activity, were pooled (Protease C).

Fractions 76 - 98, comprising 25.3% of the applicated activity, were pooled and designated Protease A.

Fractions 122 - 140, comprising 23.7% of the 30 applicated activity, were pooled and designated Protease B.

6. Affinity chromatography on a bacitracin column

The column (1.6 cm0 x 12 cm) was equilibrated with the buffer of step 1. The pool of fractions 9 - 25 were applicated on the column. The protease was eluted with the 5 same buffer with added NaCl (1 M) and isopropanol (25%). The flow rate was 5 ml/min. and the fraction size 10 ml. The elution diagram is shown in fig. 2 (OD at 280 nm vs. time). Fractions 24 - 27 comprising 73% of the applicated protease activity, were pooled and designated Protease C.

10 Example 3

Protease preparation derived from strain NCIB 12288

The same procedure as in Example 1 above was followed for the cultivation of strain NCIB 12288. The fermentation broth (0.3 1, 35 CPU/1) gave 11.7 g of crude 15 preparation with an activity of 0.39 CPU/g. Yield: 43%.

Example 4

Protease preparation derived from strain NCIB 12512

The same procedure as in Example 1 above was followed for the cultivation of strain NCIB 12512. The 20 fermentation broth (1.8 1, 30 CPU/1) gave 19.1 g of crude preparation with an activity of 1.0 CPU/g. Yield: 35%.

Example 5

Protease preparation derived from strain NCIB 12513

The same procedure as in Example 1 above was followed for the cultivation of strain NCIB 12513. The 5 resulting preparation was separated as in Example 2 above and was found to be devoid of protease B.

Example 6

Stability of Bacillus proteases in solutions of STPP, sodium perborate and TAED

Solutions, each with an activity of 0.2 CPU per litre of the protease and containing 1.75 g/l of sodium tripoly phosphate (STPP), 1.0 g/l of sodium perborate and 0.1 g/l of tetraacetyl- ethylenediamine (TAED) were incubated for 30 minutes at 40°C and 50°C. The residual activity was then measured according to the OPA-casein method, the activity after incubation at 25°C in the absence of sodium perborate and TAED being calculated as 100%. The results are presented in the following table:

| | Percent resi | dual activity |
|--------------------------|--------------|---------------|
| 20 | after 30 min | utes at |
| Protease | 40°C | 50°C |
| ALCALASE | 55 - 70 | . 5 - 17 |
| ESPERASE | 55 - 65 | 20 - 45 |
| SAVINASE | 40 - 50 | 0 - 10 |
| 25 Protease of Example 1 | 90 - 100 | 60 - 75 |
| Protease of Example 3 | 95 - 100 | 70 |
| Protease A of Example 2 | . 91 | 65 - 70 |
| | | |

Example 7

Washing Trials with Crude Protease Preparation

Washing tests were performed in a Terg-O-tometer (as described in Jay C. Harris: "Detergency Evaluation and 5 Testing", Interscience Publishers Ltd. (1954), p. 60-61) at an agitation rate of 100 rpm for 10 minutes at 60°C with EMPA 116 test fabric swatches, 5 cm x 10 cm (cotton soiled with blood, milk, and carbon black), supplied by Eidgenössische Materialprüfungs- und Versuchsanstalt, Sankt Gallen,

10 Switzerland. The following detergent compositions A and B were used in water of 9° German Hardness:

| | | | Detergent A (g/l) | Detergent B (g/l) |
|----|--------|-----------|-------------------|-------------------|
| | LAS | | 1.0 | 1.0 |
| | Soap | · | .0.1 | 0.1 |
| 15 | STPP | • | 1.25 | . 1.25 |
| | Sodium | silicate | 0.25 | 0.25 |
| | Sodium | sulphate | 2.4 | 2.4 |
| | Sodium | perborate | none | 1.0 |
| | TAED | | none | 0.1 |
| 20 | рH | | 9.5 | 9.5 |

wherein

LAS is linear alkylsulfonate (NANSA 80S, produced by Albright & Wilson)

STPP is sodium tripolyphosphate

25 TAED is tetraacetylethylenediamine.

The cloth to liquid ratio was 9 swatches per 900 ml of detergent solution. The detergent enzymes used were the enzyme preparation of Example 1 and ALCALASE protease, both at dosage levels of 0.05, 0.1 and 0.5 CPU/1.

The results of duplicate washing tests with detergents A and B are shown in Fig. 5 and 6, respectively, wherein the washing efficiency is expressed as medium values

of % Remission as determined by remission photometry by using a ZEISS ELREPHO photometer at 460 nm. The figure shows that the washing effect of the protease of this invention at dosage levels of about 0.05 CPU/l and above exceeds that of the ALCALASE protease both in the absence (Detergent A) and presence (Detergent B) of perborate + TAED.

Example 8

Washing trials with constituent proteases A, B and C

Washing tests were preformed in a Terg-O-tometer at 10 100 rpm for 10 min at 50°C. The following detergent composition was used in water of 9° German hardness:

| | ·LAS | 0.4 | g/l |
|----|------------------|------|-----|
| | AE · | 0.15 | g/l |
| | Soap | 0.15 | g/l |
| 15 | STPP | 1.75 | g/l |
| | Sodium silicate | 0.4 | g/l |
| | CMC | 0.05 | g/l |
| | EDTA | 0.01 | g/l |
| | Sodium sulphate | 2.1 | g/l |
| 20 | Sodium perborate | 1.0 | g/l |
| | TAED | 0.1 | g/I |
| | рН | 9.5 | |

wherein

LAS, STPP and TAED are as in Example 7.

25 AE is alcohol ethoxylate (Berol 065, produced by Berol Kemi AB, Sweden).

Clean swatches consisted of white cotton textile, which was desized with amylase (BAN Novo), dried and cut inpieces (10 x 20 cm).

Clean swatches were immersed in spinach juice, squeezed between two rollers and dried in a tumbler at 60°C. This was repeated twice to obtain soiled swatches.

The cloth to liquid ratio was 8 swatches (4 clean 5 and 4 soiled) in 800 ml of detergent solution. Protease A, B and C from Example 2 were tested at dosages of 0.1, 0.5 and 1.0 CPU/1. The results are shown in fig. 7 as %. Remission at 460 nm versus protease dosage.

The figure shows that all three constituent 10 proteases have a good washing effect in detergent with perborate at 50°C.

Example 9

Storage stability in liquid detergents

Liquid detergents were formulated as follows (amounts in q):

| 5 | | | • | | |
|----|---------------------------------------|-----------|-----------|-----------|-----------|
| | | A1/2 | B1/2 | C1/2 | D1/2 |
| | Fraction I: | | | | |
| | Water | 30.0/42.0 | 30.0/42.0 | 5.0/17.0 | 28.0/40.0 |
| | TEA | 10.0 | 10.0 | 10.0 | 10.0 |
| | CaCl ₂ , 2H ₂ O | 0.10 | 0.10 | 0.10 | 0.10 |
| 10 | DTPA | 0.10 | 0:10 | 0.10 | 0.10 |
| | DG | - | - | - | _ |
| | Tri-sodium Citrate | 5.0 | 5.0 | 5.0 | 5.0 |
| | H ₃ BO ₃ | 0/5.0 | 0/5.0 | 0/5.0 | 0/5.0 |
| | | | | | |
| | • | - | - | | |
|] | Fraction II: | | • | | • |
| 15 | MPG · | 0/12.5 | 0/12.5 | 0/12.5 | 0/12.5 |
| | Ethanol, 96% | 7.0 | 7.0 | 7.0 | 7.0 |
| | Oleic acid | 5.0 | 5.0 | 5.0 | 5.0 |
| | AE | 15.0 | 15.0 | 15.0 | 15.0 |
| | AES | 25.0 | 25.0 | _ | 25.0 |
| 20 | LAS | - | - | 50.0 | - |
| | | | | | |
|] | O N NaOH to pH: | 9.0 | 10.0 | 9.0 | 9.0 |
| M | Mater added to (g): | 100/129.7 | 100/129.7 | 100/129.7 | 100/129.7 |

TEA stands for triethanolamine, DTPA for pentasodium salt of diethylene-triamine-pentaacetate, DG for

25 sodium diglycolate, MPG for mono-propylene glycol, AES for
alcohol-ethoxy sulphate (Dobanol 25-3S/60, product of Shell),
LAS for linear alkyl-benzene sulphonate (Nansa 1169P), and AE
stands for alcohol ehtoxylate (Berol 160, product of Berol
Kemi AB, Sweden). In each case, the ingredients in fraction I

30 and II were mixed, and then fraction II was added slowly to
fraction I while stirring.

The water content (including water contained in other ingredients) was about 41% w/w in all detergents.

The following protease preparations were tested:

- The lyophilized crude preparation of Example 2, dissolved in a mixture of water and MPG (1:1 by weight) and diluted to an activity of 2.5 AU/g.
 - Alcalase 2.5L (product of Novo Industri A/S, Denmark), a commercial liquid preparation of alkaline protease from Bacillus licheniformis.
- 10 Esperase 8.0L (product of Novo Industri A/S, Denmark), a commercial liquid preparation of alkaline <u>Bacillus</u> protease prepared according to US 3,723,250.

The calcium content of each protease preparation was adjusted to 1.0% w/w (as Ca⁺⁺) by addition of CaCl₂,

15 2H₂O. In each experiment, 1% w/w of a protease preparation (after Ca⁺⁺ adjustment) was added to one of the above detergents, the mixture was incubated at 50°C, and samples were taken after 0, 23, 47 and 134 hours incubation. The protease activity of each sample was determined, and the 20 results are shown below, expressed as residual activity in % of initial activity (i.e. activity after 0 days). pH was measured after 0 and 134 hours.

pH:

| | | 0 h | 134 h | _0 h | 134 h |
|----|-----------|------|-------|------|-------|
| | Detergent | A | .1 | A | 2 |
| | Ex. 2 | 9.0 | 9.0 | 9.0 | 9.0 |
| 5 | ESPERASE | 9.0 | 9.1 | 9.0 | 9.0 |
| | ALCALASE | 9.0 | 9.1 | 8.9 | 9.0 |
| | Detergent | В | 1 ·. | В2 | ! |
| | Ex. 2 | 10.0 | 9.9 | 9.9 | 9,9 |
| | ESPERASE | 10.1 | 9.8 | 9.9 | 9.8 |
| 10 | ALCALASE | 10.1 | 9.8 | 9.9 | 9.8 |
| | Detergent | c. | 1 | C2 | |
| | Ex. 2 | 9.2 | 9.2 | 9.0 | 9.0 |
| | ESPERASE | 9.2 | 9.2. | 9.0 | 9.0 |
| | ALCALASE | 9.2 | 9.2 | 9.0 | 9.1 |
| 15 | Detergent | D] | | · D2 | |
| | Ex. 2 | 9.1 | 9.2 | 9.1 | 9.0 |
| | ESPERASE | 9.2 | 9.1 | 9.1 | 9.0 |
| | ALCALASE | 9.2 | 9.1 | 9.1 | 9.0 |
| | | | | | |

% residual activity:

| | | 23 h | 47 h | 134 h | 23 h | 47 h | 134 h |
|----|------------|---------------|---------------|------------|---------------|-----------------|---------------|
| | Detergent | | Al | | | A2 | |
| | Ex. 2 | 46 | 37 | 16 | 102 | 90 | 86 |
| 5 | ESPERASE | 3 | 2 | 1 | 72 | 77 | 53 |
| | ALCALASE . | ۷ 1 | 41 | 4 1 | 1 | 1 | 41 |
| | Detergent | | Bl | | | B2 . | |
| | Ex. 2 | 43 | 33 | 12 | 91 | 80 | 5,5 |
| | ESPERASE | 2 | 2 | < 1 | 67 | 70 | 39 |
| 10 | ALCALASE | < 1 | 〈 1 | ۷ 1 | < 1 | < 1 | < 1 |
| | Detergent | | Cl | | | C2 | |
| | Ex. 2 | 38 | 31 | 16 | 89 | 80 | 66 |
| | ESPERASE | 2 | 2 | 21 | 73 | 72 | 41. |
| | ALCALASE | < 1 | < 1 | <1 | 15 | 13 | 3 |
| 15 | Detergent | | Dl | • | | D2 . | |
| | Ex. 2 | 46 | 37 | 19 | 92 | 87 [.] | 75 |
| | ESPERASE | 9 | 5 | 1 | 90 | 88 | 66 |
| | ALCALASE | < 1 | < 1 | < 1 | 4 | 4 | 1 |

pH was nearly constant in all experiments. It is
20 seen that protease of the invention is more stable than
Esperase and Alcalase in all the detergent formulations
tested. The results further show that borate and MPG are very
effective as stabilizers for protease of the invention in
liquid detergents.

Form PCT/RO134 (January 1981)

| International Application No: PCT/ / |
|--|
| MICROORGANISMS |
| Optional Sheet in connection with the microorganism referred to on page 6, line 10 of the description 1 |
| A. IDENTIFICATION OF DEPOSIT! |
| Further deposits are identified on an additional shoot . Bacillus sp.nov. |
| Name of depositary inethiction 4 |
| National Collection of Industrial Bacteria (NCIB) |
| Address of depositary institution (including postal code and country) s |
| c/o the National Collection of Industrial and Marine |
| Bacteria Ltd. Torry Research Station, P.O. Box 31, 135 Abbey Road, Aberdeen AR9 8DG, United Kingdom |
| Date of deposit 5 Accession Number 6 |
| 8 July 1986 (08.07.86) NCIB 12288 |
| B. ADDITIONAL INDICATIONS T (leave blank if not applicable). This information is continued on a separate attached sheet |
| |
| In respect of those designations in which a European patent is sought, a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample. (Rule 28(4) EPC). |
| C. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE! (If the indications are not for all designated States) |
| |
| · |
| |
| |
| |
| |
| D. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable) |
| The indications listed below will be submitted to the international Sureau lister * (Specify the general nature of the indications a.g., |
| "Accession Number of Deposit") |
| |
| |
| • |
| |
| |
| |
| E. This sheet was received with the international application when filed (to be checked by the receiving Office) |
| |
| |
| (Authorized Officer) |
| The date of except (from the applicant) by the International Sureau 16 |
| |
| |
| |

| * International Application No: PCT/ / |
|---|
| MICROORGANISMS |
| Optional Sheet in connection with the microorganism referred to an page 6 the 11 of the description t |
| A. HERTHICATION OF DEPOSIT |
| Further deposits are identified on an additional sheet Bacillus sp.nov. |
| Name of depository institution 6 |
| National Collection of Industrial Bacteria (NCIB) |
| Address of depository institution (including postal code and country) s |
| c/o the National Collection of Industrial and Marine |
| Bacteria Ltd. Torry Research Station, P.O. Box 31, 135 Abbey Road, Aberdeen AB9 8DG, United Kingdom |
| Date of depoint 1 Acception Number 4 |
| 8 July 1986 (08.07.86) NCIB 12289 |
| B. ADDITIONAL INDICATIONS 1 (leave blank if not applicable). This information to continued on a separate attached shoot |
| In respect of those designations in which a European patent is sought, a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn, or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample. (Rule 28(4) EPC). |
| C. BESIGNATED STATES FOR WHICH INDICATIONS ARE MADE ! (If the indications are not for all designated States) |
| |
| D. SEPARATE FURNISHING OF INDICATIONS + (neare blank if not applicable) |
| The indications lated below will be submitted to the international Bursou later * (Specify the general nature of the indications as "Accession Number of Deposit") |
| E. This sheet was received with the international application when filed (to be checked by the receiving Office) |
| (Authorized Officer) |
| The date of seceipt (from the applicant) by the International Bureau 19 |
| |
| (Authorized Officer) |

Form PCT/RO/134 (January 1981)

| * International Application No: PCT/ / |
|--|
| MICROORGANISMS |
| Optional Shart in pennection with the microorganism referred to on page 6 the 12 of the description is |
| A. IDENTIFICATION OF DEPOSIT 9 |
| Further deposits are identified an an additional about Bacillus sp.nov. |
| Name of depository indiffusion 4 |
| National Collection of Industrial Bacteria (NCIB) |
| Address of depositary inathution (including postal code and country) 4 |
| c/o the National Collection of Industrial and Marine Bacteria Ltd. Torry Research Station, P.O. Box 3I, 135 \hbey Road, Aberdeen AB9 8DG, United Kingdom Data of Separate Number 4 |
| 5 August 1987 (05.08.87) NCIB 12512 |
| B. ADDITIONAL INDICATIONS I (heave blank if not applicable). This information is continued on a separate attached about |
| In respect of those designations in which a European patent is sought, a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample. (Rule 28(4) EPC). |
| C. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE? (If the indications are not for all designated States) |
| |
| D. SEPARATE FURNISHING OF INDICATIONS & (neare blank if not applicable) |
| The indications listed below will be submitted to the informational Burseu lister ⁹ (Specify the general nature of the indications e.g. *Accesses: Number of Deposit*) |
| |
| E. This sheet was received with the international application when filed (to be checked by the receiving Office) |
| (Authorized Officer) |
| The dats of secupit (from the septicant) by the International Bursey 19 |
| |
| (Authorized Officer) |


| International Application No: PCT/ / |
|--|
| MICROORGANISMS |
| Optional Short in connection with the microorganism referred to an page 6 the description i |
| A. INCHTWICATION OF DEPOSIT! |
| Further deposits are identified on an additional shoot . Bacillus sp.nov. |
| Stame of depository inethicition 4 |
| National Collection of Industrial Bacteria (NCIB) |
| Address of depochary inathroon (including poets) code and country) 4 |
| c/o the National Collection of Industrial and Marine Bacteria Ltd. Torry Research Station, P.O. Box 31, |
| 135 Abbey Road, Aberdeen AB9 8DG, United Kingdom |
| Date of deposit 6 Accession Number 6 |
| 5 August 1987 (05.08.87) NCIB 12513 |
| B. ADDITIONAL INDICATIONS 1 (leave blank if not applicable). This information to continued on a separate attached sheet |
| In respect of those designations in which a European patent is sought, a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample. (Rule 28(4) EPC). |
| C. BESIGNATED STATES FOR WHICH INDICATIONS ARE MADE ! (If the indications are not for all designated States) |
| |
| D. SEPARATE FURNISHING OF INDICATIONS & Deeve blank if not applicable) |
| The indications listed below will be submitted to the international Surgeu later * (Specify the general nature of the indications a.s., "Accession Number of Deposit") |
| |
| |
| |
| |
| |
| E This short was received with the international application when filed (to be checked by the receiving Office) |
| |
| (Authorized Officer) |
| The date of securpt (from the applicant) by the International Bureau 19 |
| (Authorized Officer) |

CLAIMS

- 1. A protease preparation comprising alkaline protease derived from a novel alkalophilic <u>Bacillus</u> species defined by the strains NCIB 12288 and NCIB 12289 which


 5 alkaline protease retains a residual activity measured in Casein Protease Units (CPU) after 30 minutes at pH 9.5 in a solution of 1.75 g/l of sodium tripolyphospate (STPP), 1.0 g/l of sodium perborate and 0.1 g/l of tetraacetylethylenediamine (TAED) of at least 80% and 60% at temperatures of 40°C and 50°C, respectively, of the residual activity at 25°C in the absence of sodium perborate and TAED.
- 2. A protease preparation comprising at least 10% by activity in CPU of a constituent protease A which is immunochemically identical to the protease identified by the 15 position of peak A in fig. 1 of the accompanying drawings and has the following additional characteristics: a molecular weight of about 41.5 kD, an isoelectric point of about 9.3, a specific activity of at least 150 Anson Units and 250 Hemoglobin Protease Units (AU and HPU, respectively) per gm 20 of protein, and a residual activity measured in CPU after 30 minutes at pH 9.5 in a solution of sodium tripolyphosphate (STPP, 1.75 g/1), sodium perborate (1.0 g/1), and tetraacetylethylenediamine (TAED, 0.1 g/1) of at least 80% and 60% of temperatures of 40°C and 50°C, respectively, of 25 the residual activity at 25°C in the absence of sodium perborate and TAED.
 - 3. The protease preparation of claim 2 which is essentially devoid of other proteases than said first protease A.
- 4. The protease preparation of claim 2, wherein the balance of the protease activity is provided jointly by proteases B and C or singly by either of these, said proteases being identified by peak B of fig. 1 and by peak C of fig. 1 and 2, by molecular weights of about 28.5 and 31.0 35 kD by isoelectric points of about 8.8 and 5.2, respectively, said proteases B and C being immunochemically identical to each other, but different from said protease A.

- 5. A protease preparation comprising essentially said protease B.
- 6. A protease preparation comprising essentially said protease C.
- 7. A method for producing a protease preparation, which process is characterized by cultivating a strain of the novel <u>Bacillus</u> species defined by the strains NCIB 12288 and NCIB 12289 under aerobic conditions in a nutrient medium containing assimilable sources of carbon, nitrogen, and 0 phosphorus, preferably followed by recovery of the protease
- 10 phosphorus, preferably followed by recovery of the protease preparation from the fermentation broth.
 - 8. The method of claim 7, wherein the fermentation is conducted with a strain of the <u>Bacillus</u> species defined above, which strain is mutated so as to essentially block its
- 15 capability of synthesizing one or two of the constituent proteases whilst maintaining its capability of producing the remaining constituent protease or proteases.
- 9. The method of claim 7, wherein the fermentation is conducted with a <u>Bacillus</u> strain selected from the group 20 consisting of NCIB 12288, NCIB 12289, JP 75 and JP 170.
- 10. A cleaning agent containing an effective amount, preferably at least 0.1 AU, more preferred from 0.5 to 10 AU, of the protease preparation of any one of the claims 1 to 6 and/or protease preparation produced by the 25 method of any one of the claims 7 to 9.



٠,

Fraction



TIME, MINUTES

Fig. 2




Fig. 3




Fig. 4




Fig. 5





Fig. 6



INTERNATIONAL SEARCH REPORT

PCT/DK87/00101 -

international Application No

| According to International Plants (Issuellation (1975) to both National Classification apply, indicate all) * C 12 N 9/54, C 11 D 3/386 II. FIELDS SEARCHED Minimum Documentation Searched of Classification and IPC | (Manianonia) Application 170 | | | | |
|--|------------------------------|---|--|---|----------------------------|
| Classification System Classification Symbols Classification System Classification Symbols Classification Symbols | | | | | |
| C 12 N 9/54, C 11 D 3/386 II. FIELDS SEARCHED Minimum Documentation Searched ? Classification System Classification Symbols IPC 4 US C1 Documentation Searched other than Minimum Documentation to the Estural that each Document are included in the Fields Searched . SE, NO, DK, FI Classes as above III. DOCUMENTS CONSIDERED TO BE RELEVANT* Category* Category* Category* GB, A, 1 243 784 (NOVO TERAPEUTISK LABORA— TORTUM A/S) NL, 6814166 DE, 1800508 FR, 1587801 BE, 721730 US, 3723250 CH, 538539 CA, 954807 AT, 315331 AT, 299101 GB, 1234445 X Kirk—Othmer, "Encyclopedia of chemical technology" Volume 9, 1980, John Wiley & Sons, New York, p. 138–147, see p. 140 table 2. X US, A, 3 827 938 (NOVO TERAPEUTISK LABORA— TORTUM A/S) 6 August 1974 See column 1, line 28–30. *Special categories of cited documents: 19 "A cocument defining the general state of the art which is not considered to be of particular relevance." "Special categories of cited documents: 19 "A cocument defining the general state of the art which is not considered to be of particular relevance." "Special categories of cited documents: 19 "A cocument defining the general state of the art which is not considered to be of particular relevance." "Special categories of cited documents: 19 "A cocument defining the general state of the art which is not relevance to be of particular relevance." "Special categories of cited documents: 19 "A cocument defining the general state of the art which is not relevance to be of particular relevance." "Special categories of cited documents: 19 "A cocument defining the general state of the art which is not relevance." "Special categories of cited documents: 19 "A cocument defining the general state of the art which is not relevance." "Special categories of cited documents: 19 "A cocument defining the general state of the art which is not relevance." "Special categories of cited documents: 19 "A cocument defining the art of the particular series are assembled to relevance the categories of the pa | According | g to international | Patent Classification (IPC) or to both Na | tional Classification and IPC | , |
| Classification System Clas | C 12 | N 9/54. | . C 11 D 3/386 | 4 | |
| Minimum Documentation Searched Classification Symbols IPC 4 | <u> </u> | | | | |
| Classification System IPC 4 US C1 IPS: 62, 66; 435: 221 Documentation Searched other than Minimum Documentation to the Estant that such Documents are included in the Fields Searched* SE, NO, DK, FI classes as above III. DOCUMENTS CONSIDERED TO BE RELEVANT? Support* Citation of Document, "with indication, where appropriate, of the referent passages " Relevant to Claim No. ") X GB, A, 1 243 784 (NOVO TERAPEUTISK LABORATORIUM A/S) & NL, 6814166 DE, 1800508 FR, 1587801 BE, 721730 US, 3723250 CH, 538539 CA, 954807 AT, 315331 AT, 299101 GB, 1234445 X Kirk-Othmer, "Encyclopedia of chemical technology" Volume 9, 1980, John Wiley & Sons, New York, p. 138-147, see p. 140 table 2. X US, A, 3 827 938 (NOVO TERAPEUTISK LABORATORIUM A/S) 6 August 1974 See column 1, line 28-30. **Special categories of cited documents: " **Countered to be of spaticial relevances: the claimed investion cannot be considered to be of spaticial relevances: the claimed investion cannot be considered to be of spaticial relevances: the claimed investion cannot be considered to make a considered to be of spaticial relevances: the claimed investion cannot be considered to make a considered to be considered to make a consoleration being obvious to a person s | II. FIELD | S SEARCHED | | | |
| IPC 4 US C1 195: 62, 66; 435: 221 Decumentation Searched other than Minimum Documentation to the Extent that such Decuments are included in the Flatid's Searched* SE, NO, DK, FI classes as above III. DOCUMENTS CONSIDERED TO BE RELEVANT* Category* Citation of Document, "with indication, where appropriate, of the relevant passages " Relevant to Claim No. "2 X GB, A, 1 243 784 (NOVO TERAPEUTISK LABORA— 1-10 TORIUM A/S) & NL, 6814166 DE, 1800508 FF, 1587801 BE, 721730 US, 3723250 CH, 538539 CA, 954807 AT, 315331 AT, 299101 GB, 1234445 X Kirk-Othmer, "Encyclopedia of Chemical technology" Volume 9, 1980, John Wiley & Sons, New York, p. 138-147, see p. 140 table 2. X US, A, 3 827 938 (NOVO TERAPEUTISK LABORA— 1-10 **Operation of the property | | | Minimum Docume | entation Searched 7 | |
| Decumentation Searched other than Minimum Documentation to the Estant that such Documents are included in the Fleids Searched* SE, NO, DK, FI classes as above III. DOCUMENTS CONSIDERED TO BE RELEVANT* Category* Citation of Document, "I with indication, where appropriate, of the relevant passages "I Relevant to Citalm No. "I TORIUM A/S) & NI, 681 4166 DE, 1800508 FR, 1587801 BE, 721730 US, 3723250 CH, 538539 CA, 954807 AT, 315331 AT, 299101 GB, 1234445 X Kirk-Othmer, "Encyclopedia of chemical technology" Volume 9, 1980, John Wiley & Sons, New York, p. 138-147, see p. 140 table 2. X US, A, 3 827 938 (NOVO TERAPEUTISK LABORA-TORIUM A/S) 6 August 1974 See column 1, line 28-30. **Torium A/S) 6 August 1974 See column 1, line 28-30. **Torium A/S) **Special categories of cited documents: 10 **Torium A/S) 6 August 1974 See column 1, line 28-30. **Torium A/S) 6 August 1974 See column 1 in the priority claim(s) or which is cited to establish the publication date of another or collection of the means **Torium A/S) **Torium | Classificati | ion System | | Classification Symbols | |
| Decumentation Searched other than Minimum Documentation to the Estant that such Documents are included in the Fleids Searched* SE, NO, DK, FI classes as above III. DOCUMENTS CONSIDERED TO BE RELEVANT* Category* Citation of Document, "I with indication, where appropriate, of the relevant passages "I Relevant to Citalm No. "I TORIUM A/S) & NI, 681 4166 DE, 1800508 FR, 1587801 BE, 721730 US, 3723250 CH, 538539 CA, 954807 AT, 315331 AT, 299101 GB, 1234445 X Kirk-Othmer, "Encyclopedia of chemical technology" Volume 9, 1980, John Wiley & Sons, New York, p. 138-147, see p. 140 table 2. X US, A, 3 827 938 (NOVO TERAPEUTISK LABORA-TORIUM A/S) 6 August 1974 See column 1, line 28-30. **Torium A/S) 6 August 1974 See column 1, line 28-30. **Torium A/S) **Special categories of cited documents: 10 **Torium A/S) 6 August 1974 See column 1, line 28-30. **Torium A/S) 6 August 1974 See column 1 in the priority claim(s) or which is cited to establish the publication date of another or collection of the means **Torium A/S) **Torium | TDC | 1 1 0 | 12 N 9/54 /56 C | 11 D 3/386 | |
| Documentation Searched other than Minimum Documentation to the Estant that such Documents are included in the Field's Searched. SE, NO, DK, FI classes as above III. DOCUMENTS CONSIDERED TO BE RELEVANT. Category* Citation of Document, "with indication, where appropriate, of the relevant passages." Relevant to Claim No. 19 X GB, A, 1 243 784 (NOVO TERAPEUTISK LABORA— TORIUM A/S) & NL, 681 4166 DE, 1800508 FR, 1587801 BE, 721730 US, 3723250 CH, 538539 CA, 954807 AT, 315331 AT, 299101 GB, 1234445 X Kirk-Othmer, "Encyclopedia of chemical technology" Volume 9, 1980, John Wiley & Sons, New York, p. 138-147, see p. 140 table 2. X US, A, 3 827 938 (NOVO TERAPEUTISK LABORA— TORIUM A/S) 6 August 1974 See column 1, line 28-30. **Special categories of cited documents: 10 carried to the of particular relevance considered to be of particular relevance. **Special categories of cited documents: 10 carried to the office of the considered to the office of the considered to the office of particular relevance. **Special categories of cited documents: 10 carried to the office of the considered to the office of the considered to the office of particular relevance. **Special categories of cited documents: 10 carried to the office of the considered to the office of the considered to the office of particular relevance. **Cocument defining the general state of the sit which is not candidared to be of particular relevance. **Cocument defining the general state of the sit which is not candidared to be of particular relevance. **Cocument defining the general state of the sit which is not candidared to the office of particular relevance. **Cocument defining the general state of the sit which is not candidared to the office of particular relevance. **Cocument defining the general state of the sit which is not candidared to the office of particular relevance. **Cocument defining the general state of the sit which is not candidared to the considered to the candidared to the considered to the considered to the complete with the | | | | | |
| SE, NO, DK, FI classes as above III. DOCUMENTS CONSIDERED TO BE RELEVANT* Category* Clation of Document, 1" with indication, where appropriate, of the relevant passages 12 Relevant to Claim No. 12 X GB, A, 1 243 784 (NOVO TERAPEUTISK LABORA— 1-10 TORIUM A/S) & NL, 68141.66 DE, 1800508 FR, 1587801 BE, 721730 US, 3723250 CH, 538539 CA, 954807 AT, 315331 AT, 299101 GB, 1234445 X Kirk-Othmer, "Encyclopedia of chemical technology" Volume 9, 1980, John Wiley & Sons, New York, p. 138-147, see p. 140 table 2. X US, A, 3 827 938 (NOVO TERAPEUTISK LABORA— 1-10 TORIUM A/S) 6 August 1974 See column 1, line 28-30. *Special categories of cited documents: 10 "A" document defining the general state of the art which is not considered to be of particular relevance. Every comment defining the general state of the art which is not considered to be of particular relevance. The comment defining the general state of the art which is not considered to be of particular relevance. The comment defining the general state of the art which is not considered to be of particular relevance. The comment defining the general state of the art which is not considered to be particular relevance. The comment defining the general state of the art which is not considered to the considered to involve an inventive step when the document relevance to a practical relation of the same pattent family """ document relevance the the claimed invention ca | 05 0 | - | $\frac{195}{2}$. 02, 00, $\frac{495}{2}$. 2 | 2.1 | |
| SE, NO, DK, FI classes as above III. DOCUMENTS CONSIDERED TO BE RELEVANT* Category* Clation of Document, 1" with indication, where appropriate, of the relevant passages 12 Relevant to Claim No. 12 X GB, A, 1 243 784 (NOVO TERAPEUTISK LABORA— 1-10 TORIUM A/S) & NL, 68141.66 DE, 1800508 FR, 1587801 BE, 721730 US, 3723250 CH, 538539 CA, 954807 AT, 315331 AT, 299101 GB, 1234445 X Kirk-Othmer, "Encyclopedia of chemical technology" Volume 9, 1980, John Wiley & Sons, New York, p. 138-147, see p. 140 table 2. X US, A, 3 827 938 (NOVO TERAPEUTISK LABORA— 1-10 TORIUM A/S) 6 August 1974 See column 1, line 28-30. *Special categories of cited documents: 10 "A" document defining the general state of the art which is not considered to be of particular relevance. Every comment defining the general state of the art which is not considered to be of particular relevance. The comment defining the general state of the art which is not considered to be of particular relevance. The comment defining the general state of the art which is not considered to be of particular relevance. The comment defining the general state of the art which is not considered to be particular relevance. The comment defining the general state of the art which is not considered to the considered to involve an inventive step when the document relevance to a practical relation of the same pattent family """ document relevance the the claimed invention ca | | | | Maria Danis | |
| III. DOCUMENTS CONSIDERED TO BE RELEVANT? Category* Citation of Document, "with Indication, where appropriate, of the relevant passages 12 Relevant to Claim No. 13 X GB, A, 1 243 784 (NOVO TERAPEUTISK LABORA— TORTUM A/S) & NL, 68141.66 DE, 1800508 FR, 1587801 BE, 721730 US, 3723250 CH, 538539 CA, 954807 AT, 315331 AT, 299101 GB, 1234445 X Kirk-Othmer, "Encyclopedia of chemical technology" Volume 9, 1980, John Wiley & Sons, New York, p. 138-147, see p. 140 table 2. X US, A, 3 827 938 (NOVO TERAPEUTISK LABORA— 1-10 **TORTUM A/S) 6 August 1974 See Column 1, line 28-30. **Special categories of cited documents: 19 **A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document of path of the publication date of another claim or other special reason (as specified) **Courset which may throw doubts on priority claim(s) or whom the considered to be of particular relevance to the reason of the relevance of the reason of th | | | Documentation Searched other | s are included in the Fields Searched | |
| III. DOCUMENTS CONSIDERED TO BE RELEVANT? Category* Citation of Document, "I with Indication, where appropriate, of the relevant passages 19 Relevant to Claim No. 19 X GB, A, 1 243 784 (NOVO TERAPEUTISK LABORA— TORIUM A/S) & NL, 681,4166 DE, 1800508 FR, 1587801 BE, 721730 US, 3723250 CH, 538539 CA, 954807 AT, 315331 AT, 299101 GB, 1234445 X Kirk-Othmer, "Encyclopedia of chemical tech— nology" Volume 9, 1980, John Wiley & Sons, New York, p. 138–147, see p. 140 table 2. X US, A, 3 827 938 (NOVO TERAPEUTISK LABORA— TORIUM A/S) 6 August 1974 See column 1, line 28–30. *Special categories of cited documents: 19 "A document admining the general state of the art which is not canadased to be of predictor relevance." "E earlier document which may throw doubts on priority claim(s) or which is cited to establish the published on or after the international filing date or which is cited to establish the published on or after the international filing date or which is cited to establish the published on or after the international filing date or which is cited to establish the published on or after the international filing date or other management of the annual filing date but that the priority date claimed invention cannot be considered novel or cannot be considered to every uncertifying the relevance in the claimed invention cannot be considered to every uncertifying the relevance in the claimed invention cannot be considered to every uncertifying the relevance in the claimed invention cannot be considered to every uncertifying the relevance in the claimed invention cannot be considered to every uncertifying the relevance in the claimed invention cannot be considered on the considered to every cannot be considered to every cannot be considered on the considered to every cannot be co | | | to the Extent that been become | | |
| III. DOCUMENTS CONSIDERED TO BE RELEVANT? Category* Citation of Document, "I with Indication, where appropriate, of the relevant passages 19 Relevant to Claim No. 19 X GB, A, 1 243 784 (NOVO TERAPEUTISK LABORA— TORIUM A/S) & NL, 681,4166 DE, 1800508 FR, 1587801 BE, 721730 US, 3723250 CH, 538539 CA, 954807 AT, 315331 AT, 299101 GB, 1234445 X Kirk-Othmer, "Encyclopedia of chemical tech— nology" Volume 9, 1980, John Wiley & Sons, New York, p. 138–147, see p. 140 table 2. X US, A, 3 827 938 (NOVO TERAPEUTISK LABORA— TORIUM A/S) 6 August 1974 See column 1, line 28–30. *Special categories of cited documents: 19 "A document admining the general state of the art which is not canadased to be of predictor relevance." "E earlier document which may throw doubts on priority claim(s) or which is cited to establish the published on or after the international filing date or which is cited to establish the published on or after the international filing date or which is cited to establish the published on or after the international filing date or which is cited to establish the published on or after the international filing date or other management of the annual filing date but that the priority date claimed invention cannot be considered novel or cannot be considered to every uncertifying the relevance in the claimed invention cannot be considered to every uncertifying the relevance in the claimed invention cannot be considered to every uncertifying the relevance in the claimed invention cannot be considered to every uncertifying the relevance in the claimed invention cannot be considered to every uncertifying the relevance in the claimed invention cannot be considered on the considered to every cannot be considered to every cannot be considered on the considered to every cannot be co | | • | | | |
| III. DOCUMENTS CONSIDERED TO BE RELEVANT? Category* Citation of Document, "I with Indication, where appropriate, of the relevant passages 19 Relevant to Claim No. 19 X GB, A, 1 243 784 (NOVO TERAPEUTISK LABORA— TORIUM A/S) & NL, 681,4166 DE, 1800508 FR, 1587801 BE, 721730 US, 3723250 CH, 538539 CA, 954807 AT, 315331 AT, 299101 GB, 1234445 X Kirk-Othmer, "Encyclopedia of chemical tech— nology" Volume 9, 1980, John Wiley & Sons, New York, p. 138–147, see p. 140 table 2. X US, A, 3 827 938 (NOVO TERAPEUTISK LABORA— TORIUM A/S) 6 August 1974 See column 1, line 28–30. *Special categories of cited documents: 19 "A document admining the general state of the art which is not canadased to be of predictor relevance." "E earlier document which may throw doubts on priority claim(s) or which is cited to establish the published on or after the international filing date or which is cited to establish the published on or after the international filing date or which is cited to establish the published on or after the international filing date or which is cited to establish the published on or after the international filing date or other management of the annual filing date but that the priority date claimed invention cannot be considered novel or cannot be considered to every uncertifying the relevance in the claimed invention cannot be considered to every uncertifying the relevance in the claimed invention cannot be considered to every uncertifying the relevance in the claimed invention cannot be considered to every uncertifying the relevance in the claimed invention cannot be considered to every uncertifying the relevance in the claimed invention cannot be considered on the considered to every cannot be considered to every cannot be considered on the considered to every cannot be co | | ar No | DV Et alages a | a abovo | |
| Catagory* Citation of Document, " with Indication, where appropriate, of the relevant passages 13 Relevant to Claim No. 13 | | SE, NO, | DK, FI Classes a | s above | |
| X GB, A, 1 243 784 (NOVO TERAPEUTISK LABORA— TORIUM A/S) & NL, 6814166 DE, 1800508 FR, 1587801 BE, 721730 US, 3723250 CH, 538539 CA, 954807 AT, 315331 AT, 299101 GB, 1234445 X Kirk-Othmer, "Encyclopedia of chemical technology" Volume 9, 1980, John Wiley & Sons, New York, p. 138-147, see p. 140 table 2. X US, A, 3 827 938 (NOVO TERAPEUTISK LABORA— TORIUM A/S) 6 August 1974 See Column 1, line 28-30. """ decument defining the general state of the art which is not canaldated to be of particular relevance "E earlier document but published on or after the international filing date to be of particular relevance in the principle of | III. DOCL | | | | |
| **Special categories of cited documents: 19 **Ar document defining the general state of the art which is not considered to be of particular relevance in cited on or other special reason (as a specified) **Cocument defining the general state of the art which is not considered from the publication date of another citation or other special reason (as a specified) **Cocument which may thin who doubts on priority claims) or other special reason (as a specified) **Cocument which may thin who doubts on priority claims) or other special reason (as a specified) **Cocument of particular relevance; the claimed invention at | Category * | Citation of | Document, 11 with Indication, where ap | propriate, of the relevant passages 12 | Relevant to Claim No. 13 |
| **Special categories of cited documents: 19 **Ar document defining the general state of the art which is not considered to be of particular relevance in cited on or other special reason (as a specified) **Cocument defining the general state of the art which is not considered from the publication date of another citation or other special reason (as a specified) **Cocument which may thin who doubts on priority claims) or other special reason (as a specified) **Cocument which may thin who doubts on priority claims) or other special reason (as a specified) **Cocument of particular relevance; the claimed invention at | 3.5 | CD 3 | 2 242 704 (NOVO T | EDADEHMICK IABODA | 1_10 |
| **Special categories of cited documents: 10 **A" document defining the general state of the art which is not considered to be of particular relevance **E" earlier document but published on or after the international filing date **U" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) **O" document referring to an oral disclosure, use, exhibition or other means **P" document published prior to the international filing date but later than the priority date claimed **I" document published prior to the international filing date but later than the priority date claimed **V" document published prior to the international filing date but later than the priority date claimed **V" document published prior to the international filing date but later than the priority date claimed **V" document published prior to the international filing date but later than the priority date claimed **V" document published prior to the international filing date but later than the priority date claimed **V" document published prior to the international filing date but later than the priority date claimed **V" document published prior to the international filing date but later than the priority date claimed **V" document published prior to the international filing date but later than the priority date claimed **V" document published prior to the international filing date but later than the priority date claimed **V" document government than the priority date claimed **V" document government than the published prior to the international filing date but later than the priority date claimed **V" document government than the published prior to the international Search Report **J" document governmen | X | GB, A, | | ERAPEUTISK LABORA- | 1-10 |
| DE, 1800508 FR, 1587801 BE, 721730 US, 3723250 CH, 538539 CA, 954807 AT, 315331 AT, 299101 GB, 1234445 X Kirk-Othmer, "Encyclopedia of chemical technology" Volume 9, 1980, John Wiley & Sons, New York, p. 138-147, see p. 140 table 2. X US, A, 3 827 938 (NOVO TERAPEUTISK LABORA-TORIUM A/S) 6 August 1974 See column 1, line 28-30. **A document defining the general state of the art which is not considered to be of particular relevance "E" estrie document burblished on or after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the considered to be of particular relevance which is cited to establish the publication date of another which is cited to establish the publication date of another citation or other special insean (as specified) **" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the later than the priority date claimed **" document referring to an oral disclosure, use, exhibition or other special insean (as specified) **" document published prior to the international filing date but later than the priority date claimed **" document invention step when the priority claims or after the international filing date or priority date and not be considered novel or cannot be considered novel or cannot be considered to invention stanto the considered novel or cannot be considered novel or cannot | | | | | |
| FR, 1587801 BE, 721730 US, 3723250 CH, 538539 CA, 954807 AT, 315331 AT, 299101 GB, 1234445 X Kirk-Othmer, "Encyclopedia of chemical technology" Volume 9, 1980, John Wiley & Sons, New York, p. 138-147, see p. 140 table 2. X US, A, 3 827 938 (NOVO TERAPEUTISK LABORA— TORIUM A/S) 6 August 1974 See column 1, line 28-30. **Special categories of cited documents: 10 TORIUM A/S) 6 August 1974 See column 1, line 28-30. **Openent which may throw doubts on priority claim(s) or which is cited to establish the publication or other means of the means of the means of the means of the first of the priority date and not in conflict with the publication or after the international filing date """ document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other sension reasons are considered to involve an inventive step when the document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the do | | & | | | |
| BE, 721730 US, 3723250 CH, 538539 CA, 954807 AT, 315331 AT, 299101 GB, 1234445 X Kirk-Othmer, "Encyclopedia of chemical technology" Volume 9, 1980, John Wiley & Sons, New York, p. 138-147, see p. 140 table 2. X US, A, 3 827 938 (NOVO TERAPEUTISK LABORA— TORIUM A/S) 6 August 1974 See column 1, line 28-30. **Special categories of cited documents: 10 "A" document defining the general state of the art which is not considered to be of particular relevance or which is cited to establish the bubblication date or which is cited to establish the bubblication date or which is cited to establish the bubblication date or which is cited to establish the bubblication date or which is cited to establish the bubblication date or which is cited to establish the bubblication date or which is cited to establish the bubblication date or which is cited to establish the bubblication date or another considered to establish the bubblication date or which is cited to establish the bubblication date or which is cited to establish the bubblication date or which is cited to establish the bubblication date or which is cited to establish the bubblication date or which is cited to establish the bubblication date or another cannot be considered novel or cannot be considered in the art. "T" later document published after the international filling date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention accounted to particular relevance; the claimed invention | | | • | | |
| US, 3723250 CH, 538539 CA, 954807 AT, 315331 AT, 299101 GB, 1234445 X Kirk-Othmer, "Encyclopedia of chemical technology" Volume 9, 1980, John Wiley & Sons, New York, p. 138-147, see p. 140 table 2. X US, A, 3 827 938 (NOVO TERAPEUTISK LABORA— TORIUM A/S) 6 August 1974 See column 1, line 28-30. """ document defining the general state of the art which is not cansidered to be of particular relevance of the considered to be of particular relevance in the international filing date """ document which may throw doubte on priority claim(s) or which is clied to establish the publication date of another citation or other special reason (as specified) """ document referring to an oral disclosure, use, exhibition or other means """ document published prior to the international filing date but later than the priority date claimed invention cannot be considered to involve an inventive step "document of particular relevance; the claimed invention cannot be considered to involve an inventive step "document of particular relevance; the claimed invention cannot be considered to involve an inventive step "document of particular relevance; the claimed invention cannot be considered to involve an inventive step "document of particular relevance; the claimed invention cannot be considered to involve an inventive step "document of particular relevance; the claimed invention cannot be considered to involve an inventive step "document of particular relevance; the claimed invention cannot be considered to involve an inventive step "document of particular relevance; the claimed invention cannot be considered to involve an inventive step "document of particular relevance; the claimed invention cannot be considered to involve an inventive step "document of particular relevance; the claimed invention cannot be considered to involve an inventive step "document of particular relevance; the claimed invention cannot be considered to involve an inventive step "document of particular relevance; the claimed invention cannot be considered to inv | | į | - · • | | |
| CH, 538539 CA, 954807 AT, 315331 AT, 299101 GB, 1234445 X Kirk-Othmer, "Encyclopedia of chemical technology" Volume 9, 1980, John Wiley & Sons, New York, p. 138-147, see p. 140 table 2. X US, A, 3 827 938 (NOVO TERAPEUTISK LABORA— TORIUM A/S) 6 August 1974 See column 1, line 28-30. "An document defining the general state of the art which is not considered to be of particular relevance." "E earlier document but published on or after the international filing date or which is clied to establish the publication date of another citation or other special reason (as specified) "O' document which may throw doubts on priority claim(s) or which is clied to establish the publication date of another citation or other special reason (as specified) "O' document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed IV. CERTIFICATION Date of the Actual Completion of the International Search 1987 -11- 0 3 | | | • | | |
| CA, 954807 AT, 315331 AT, 299101 GB, 1234445 X Kirk-Othmer, "Encyclopedia of chemical technology" Volume 9, 1980, John Wiley & Sons, New York, p. 138-147, see p. 140 table 2. X US, A, 3 827 938 (NOVO TERAPEUTISK LABORA-TORIUM A/S) 6 August 1974 See column 1, line 28-30. *Special categories of cited documents: 10 "A" document defining the general state of the art which is not considered to be of particular relevance iffing date of the considered to be of particular relevance involve an inventive step when the citation or other special reason (as specified) "O" document other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "B" document published prior to the international filing date but later than the priority date claimed "V" document other special reason (as specified) "O" document published prior to the international filing date but later than the priority date claimed "V" CERTIFICATION Date of the Actual Completion of the International Search 1987 -11- 03 | | | | | |
| *Special categories of cited documents: 10 * Special categories of cited documents: 10 * Comment of particular relevance: the claimed invention and the considered novel or cannot be considered to involve an inventive step when the document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document in a combination being obvious to a person skilled in the art. **To document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document in a combination being obvious to a person skilled in the art. **A document member of the same patent family **Document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document in a combination being obvious to a person skilled in the art. **A document member of the same patent family **Document of particular relevance: the claimed invention cannot be considered novel or cannot be considered novel or | | | | | |
| AT, 299101 GB, 1234445 X Kirk-Othmer, "Encyclopedia of chemical technology" Volume 9, 1980, John Wiley & Sons, New York, p. 138-147, see p. 140 table 2. X US, A, 3 827 938 (NOVO TERAPEUTISK LABORA— TORIUM A/S) 6 August 1974 See column 1, line 28-30. "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filling date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication during the cited to establish the publication during the considered novel or cannot be considered to involve an inventive step when the comment published prior to the international filling date but later than the priority date claimed invention cannot be considered in the art. "O" document published prior to the international filling date but later than the priority date claimed "P" document published prior to the international filling date but later than the priority date claimed invention cannot be considered for involve an inventive step when the comment published prior to the international filling date but later than the priority date claimed "V" CERTIFICATION Date of the Actual Completion of the International Search 1-10 1-1 | | | | | |
| * Special categories of cited documents: 10 * Special categories of cited documents: 10 * Special categories of cited documents: 10 **A" document defining the general state of the art which is not cansidered to be of particular relevance: *"E" earlier document but published on or after the international filling date """ document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed *V. CERTIFICATION Date of the Actual Completion of the International Search 1-10 | | • •. | | • • | • . |
| X Kirk-Othmer, "Encyclopedia of chemical technology" Volume 9, 1980, John Wiley & Sons, New York, p. 138-147, see p. 140 table 2. X US, A, 3 827 938 (NOVO TERAPEUTISK LABORA— TORIUM A/S) 6 August 1974 See column 1, line 28-30. **Special categories of cited documents: 10 | i | ' | | | • |
| nology" Volume 9, 1980, John Wiley & Sons, New York, p. 138-147, see p. 140 table 2. X US, A, 3 827 938 (NOVO TERAPEUTISK LABORA— TORIUM A/S) 6 August 1974 See column 1, line 28-30. **Special categories of cited documents: 10 "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document referring to the international filing date but late than the priority date claimed "Y" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such document in the art. "A" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such document in the art. "A" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such document in the art. "A" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such document in the art. "A" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such document in the art. "A" document of particular relevance; the claimed invention cannot be considere | ! | | GB, 1234445 | | |
| nology" Volume 9, 1980, John Wiley & Sons, New York, p. 138-147, see p. 140 table 2. X US, A, 3 827 938 (NOVO TERAPEUTISK LABORA— TORIUM A/S) 6 August 1974 See column 1, line 28-30. **Special categories of cited documents: 10 "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document referring to the international filing date but late than the priority date claimed "Y" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such document in the art. "A" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such document in the art. "A" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such document in the art. "A" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such document in the art. "A" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such document in the art. "A" document of particular relevance; the claimed invention cannot be considere | | | 1 Hen 3 . 24 | | 1-10 |
| New York, p. 138-147, see p. 140 table 2. X US, A, 3 827 938 (NOVO TERAPEUTISK LABORA— TORIUM A/S) 6 August 1974 See column 1, line 28-30. "A" document defining the general state of the art which is not considered to be of particular relevance: "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "A" document member of the same patent family IV. CERTIFICATION Date of Melling of this international Search 1987 -11- 0 3 | X | Kirk-Ot | hmer, "Encyclopedi | a of chemical tech- | 1-10 |
| **Special categories of cited documents: 10 **Special categories of cited documents: 10 **A" document defining the general state of the art which is not considered to be of particular relevance *E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed IV. CERTIFICATION Date of the Actual Completion of the International Search 1-10 "T" later document published after the international filing date or priority date and not in conflict with the application but considers the priority date and not in conflict with the application but considers and not in conflict with the application but considers and not in conflict with the application but considers and not in conflict with the application but considers and not in conflict with the application but considers and not in conflict with the application but considers and not in conflict with the application but considers and not in conflict with the application but considers and not in conflict with the application but considers and not in conflict with the application but considers and not in conflict with the application but considers and not in conflict with the application but considered to involve an inventive step "" """ document referring to an oral disclosure, use, exhibition or other special reason (as specified) """ document priority date and not in conflict with the application but considered novel or cannot be considered novel or cannot be considered novel or cannot be considered to involve an inventive step when the document is combined with one or more other such document and inventive step when the document is combined with one or more other such document prior to the international f | į | norogy | Volume 9, 1980, 3 | onn wiley & sons, | |
| **Special categories of cited documents: 10 **A" document defining the general state of the art which is not considered to be of particular relevance *E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another cliation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed IV. CERTIFICATION Date of the Actual Completion of the International Search 1987 -11- 0 3 | | New Yor | k, p. 138-14/, see | p. 140 table 2. | |
| **Special categories of cited documents: 10 **A" document defining the general state of the art which is not considered to be of particular relevance *E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another cliation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed IV. CERTIFICATION Date of the Actual Completion of the International Search 1987 -11- 0 3 | ! | | | TO A DOUBLEY A A DODA | 1 10 |
| *Special categories of cited documents: 10 "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "V. CERTIFICATION Date of the Actual Completion of the International Search 1987 -10-21 "T" later document published after the International filing date or priority date and not in conflict with the application but invention to pricity date and not in conflict with the application but invention or priority date and not in conflict with the application but invention of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such document, such combination being obvious to a person skilled in the art. "&" document member of the same patent family IV. CERTIFICATION Date of Mailing of this international Search Report 1987 -11- 03 | X | US, A, | | ERAPEUTISK LABORA- | 1-10 |
| * Special categories of cited documents: 10 "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the International filling date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filling date but later than the priority date claimed IV. CERTIFICATION Date of the Actual Completion of the International Search 1987-10-21 "T" later document published after the International filling date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the city date and not in conflict with the application but cited to understand the principle or theory underlying the considered novel or cannot be considered to involve an inventive step "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family IV. CERTIFICATION Date of Mailing of this International Search Report 1987-11-03 | 1 | | | | |
| *Special categories of cited documents: 10 "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filling date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filling date but later than the priority date claimed "V. CERTIFICATION Date of the Actual Completion of the International Search 1987-10-21 "T" later document published after the international filling date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such document, such combined with one or more other such document, such combined with one or more other such document, such combination being obvious to a person skilled in the art. "A" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such document, such combined with one or more other such document, such combined with one or more other such document, such combined with one or more other such document, such combined with one or more other such document. "A" document member of the same patent family IV. CERTIFICATION Date of Mailing of this International Search Report 1987 -11 - 0 3 | - 1 | | | 20 20 | |
| "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed IV. CERTIFICATION Date of the Actual Completion of the International Search 1987-10-21 Or priority date and not in confilict with the application but cited to understand the principle or theory underlying the invention of cannot be considered novel or cannot be considered novel or cannot be considered to involve an inventive step document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family IV. CERTIFICATION Date of Mailing of this international Search Report | } | | See column 1, 11n | e 28-30. | |
| "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed IV. CERTIFICATION Date of the Actual Completion of the International Search 1987-10-21 Or priority date and not in confilict with the application but cited to understand the principle or theory underlying the invention of cannot be considered novel or cannot be considered novel or cannot be considered to involve an inventive step document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family IV. CERTIFICATION Date of Mailing of this international Search Report | ļ | | | •••/••• | |
| "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed IV. CERTIFICATION Date of the Actual Completion of the International Search 1987-10-21 Or priority date and not in confilict with the application but cited to understand the principle or theory underlying the invention of cannot be considered novel or cannot be considered novel or cannot be considered to involve an inventive step document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family IV. CERTIFICATION Date of Mailing of this international Search Report | ì | | | | |
| "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed IV. CERTIFICATION Date of the Actual Completion of the International Search 1987-10-21 Or priority date and not in confilict with the application but cited to understand the principle or theory underlying the invention of cannot be considered novel or cannot be considered novel or cannot be considered to involve an inventive step document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family IV. CERTIFICATION Date of Mailing of this international Search Report | | | | | |
| "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed IV. CERTIFICATION Date of the Actual Completion of the International Search 1987-10-21 Cited to understand the principle or theory underlying the cinventor cannot be considered novel or cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family IV. CERTIFICATION Date of Mailing of this International Search Report | | | | or priority date and not in conflic | t with the application but |
| "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to livide an inventive step which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed IV. CERTIFICATION Date of the Actual Completion of the International Search 1987-10-21 "X" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family Date of Mailing of this International Search Report | "A" doci | ument defining th sidered to be of ; | e general state of the art which is not particular relevance | cited to understand the principle | or theory underlying the |
| "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed IV. CERTIFICATION Date of the Actual Completion of the International Search 1987-10-21 Involve an inventive step "O" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family 1987-10-21 | | | published on or after the International | "X" document of particular relevance | e; the claimed invention |
| which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed IV. CERTIFICATION Date of the Actual Completion of the International Search 1987-10-21 "Y" document of perticular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document of perticular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family IV. CERTIFICATION Date of Mailing of this international Search Report | "L" doci | ument which may | throw doubts on priority claim(s) or | involve an inventive step | Callings by College to |
| "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed IV. CERTIFICATION Date of the Actual Completion of the International Search 1987-10-21 document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family Oate of Mailing of this International Search Report | whic | ch is cited to est | ablish the publication date of another | "Y" document of particular relevance | e; the claimed invention |
| "P" document published prior to the international filing date but later than the priority date claimed IV. CERTIFICATION Date of the Actual Completion of the International Search 1987-10-21 Date of Mailing of this International Search Report | "O" doci | ument referring to | | document is combined with one | or more other such docu- |
| ister than the priority date claimed "2" document member of the same patent family IV. CERTIFICATION Date of the Actual Completion of the International Search 1987-10-21 1987-10-21 1987-10-03 | | | nrior to the international filling date but | in the art. | |
| Date of the Actual Completion of the International Search 1987-10-21 Date of Mailing of this International Search Report 1987-11-03 | later | than the priority | date claimed | "&" document member of the same p | atent family |
| 1987-10-21 1987 -11- 03 | | | | | |
| 1987-10-21 1987 -11- 03 | Date of the | Actual Completi | on of the International Search | Oate of Mailing of this international Sea | rch Report |
| | | | | 4007 -11- 0 2 | |
| International Searching Authority Signature of Apphorized Officer (() - () | 1987-10-21 | | | | |
| | | | | | |
| Swedich Patent Office From Siösteen | a | 1 - 1 - 1 | Offi | Avonne Siöste | areen |

| tegory * | Citation of | Document, with indication, where appropriate, of the relevant passages | Relevant to Claim No |
|----------|-------------|--|----------------------|
| | & | NL, 7207050 FR, 2140064 DE, 2224777 GB, 1395895 CH, 599975 | |
| X : | US, A, | 4 002 572 (TE NIJENHUIS) 11 January 1977 NL, 7513433 FR, 2292042 LU, 73826 BE, 835693 DE, 2551742 GB, 1519148 JP, 51082783 JP, 51125407 JP, 55148086 US, 30602 | 1-10 |
| х | US, A, | 4 052 262 (HORIKOSHI ET AL) 4 October 1977 NL, 7007854 DE, 2026092 . FR, 2052484 GB, 1308238 SE, 368961 | 1-10 |
| X : | US, A, | 3 748 233 (LEVER BROTHERS COMPANY) 24 July 1973 NL, 7013286 DE, 2044161 FR, 2061067 GB, 1306867 CH, 542279 BE, 755886 | 1-10 |
| X | US, A, | 4 052 262 (HORIKOSHI ET AL) 4 October 1977 NL, 7007854 DE, 2026092 FR, 2052484 GB, 1308238 SE, 368961 | 1-10 |
| | | •••/••• | |

| | | ERED TO BE RELEVANT (CONTINUED FROM THE SECOND SH | Relevant to Claim No |
|------------|-------------|--|----------------------|
| Category • | Citation of | Document, with indication, where appropriate, of the relevant passages | Note and to Claim to |
| x | US, A, | 4 480 037 (ICHISHIMA ET AL) 30 October 1984 See table 2. JP, 58134990 FR, 2521163 AU, 10970/83 GB, 2116561 CA, 1193213 AU, 556045 | 1-10 |
| x ! | DE, A, | 12 November 1970 | 1-10 |
| X | US, A, & | 3 905 869 (HIDAKA ET AL) 16 September 1975 FR, 2197569 DE, 2343963 CA, 990672 GB, 1451074 JP, 49042883 | 1-10 |
| x | US, A, | 3 674 643 (AUNSTRUP ET AL) 4 July 1972 See column 5, line 15-17. NL, 6815944 DE, 1807185 GB, 1205403 FR, 1599036 CH, 523319 BE, 723649 AT, 290444 SE, 372561 | 1-10 |
| x | US, A, | 3 723 250 (AUNSTRUP ET AL) 27 March 1973 NL, 6814166 DE, 1800508 FR, 1587801 GB, 1243784 BE, 721730 CH, 538539 CA, 954807 AT, 315331 AT, 299101 GB, 1234445 | 1-10 |

PCT/DK87/00101

| ategory * | NTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET Citation of Document, with indication, where appropriate, of the relevant passages | Relevant to Claim No |
|------------|---|----------------------|
| | | |
| х | Chemical abstracts, Vol 81, 1974, abstract | . 10 |
| | No 59820t, Su, Yuan-Chi et al J. Chin. | 1-10 |
| ! | Biochem. Soc. 1973 2(1), 1-10 (Eng). | |
| x | Chemical abstracts, Vol 102, 1985, abstract | 1-10 |
| : | No 202605m, NL 8302790, 8 Aug 1983. | |
| X | Chemical abstracts, Vol 96, 1982, abstract | 1-10 |
| • | No 64654f, Dambmann et al, Proc. Int. Symp. 1980 (Pub. 1981) 231-44 (Eng). | |
| ' . | _ | |
| X | Chemical abstracts, Vol 72, 1970, abstract No 14098m, Chem. Spec. Mfr. Ass. Proc. Mid- | 1-10 |
| | -Year Meet, 1969, 55, 92-8 (Eng). | |
| P : | EP, A2, 0 220 921 (GENEX CORPORATION) | 1 10 |
| : | 6 May 1987 | 1-10 |
| 1 | . | |
| | | |
| ļ | • | |
| : | | • |
| ! | • | |
| : | | |
| : | | |
| : | | |
| : | | |
| : | | |
| ì | | |
| • | · | • |
| : | | |
| : | • | |
| | | |
| | • | |
| | | |
| | | |
| | | |
| • | • | |
| i | | |
| Ì | | • |
| | | |
| | | |